Publications
Publications, Books, Book Chapters and Reviews by Prof. Marcus Maurer, MD
Use: Start with an overview of all publications. Use tag links to list selected documents or to list an entire category, e.g. Original Work, Books, Book Chapters, Reviews. If you know what you are looking for, enter this term in the search field.
Treffer: 35
Order by:- [r.171] What is the contribution of IgE to nasal polyposis? (0)
- [r.169] Differences and similarities in the mechanisms and clinical expression of bradykinin-mediated vs. mast cell-mediated angioedema (1)
- [r.162] Total IgE as marker in chronic spontaneous urticaria (0)
- [r.161] Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA), Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI), Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA), Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI), Österreichische Gesellschaft für Pneumologie (ÖGP) in co-operation with the German, Austrian, and Swiss ARIA groups, and the European Academy of Allergy and Clinical Immunology (EAACI) (2)
- [r.152] How to treat patients with chronic spontaneous urticaria with omalizumab: questions and answers (5)
- [r.143] Treatments of cold urticaria: a systematic review (4)
- [r.119] Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion (0)
- [r.105] Current and future therapies for treating chronic spontaneous urticaria (0)
- [r.094] Omalizumab for the treatment of chronic urticaria (0)
- [r.092] The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria (0)
- [r.080] Pharmacotherapy of chronic spontaneous urticaria (0)
- [o.427] Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria (0)
- [o.423] Omalizumab in children and adolescents with chronic urticaria: a 16 week real-world study (0)
- [o.421] Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response (0)
- [o.419] Expert consensus on practical aspects in the treatment of chronic urticaria (0)
- [o.417] Case Report: Omalizumab for chronic spontaneous urticaria in pregnancy (0)
- [o.415] The global impact of the COVID-19 pandemic on the management and course of chronic urticaria (0)
- [o.414] Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria (1)
- [o.412] Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria – a systematic review for the EAACI biologicals guidelines (0)
- [o.410] Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both (0)
(Last update: 08.2021)
| Number of publications (original work and reviews) in peer-reviewed journals: | 636 |
| Number of original publications in peer-reviewed journals: | 462 |
| Number of reviews in peer-reviewed journals: | 174 |
| Cumulative IF of publications (original work & reviews) in peer-reviewed journals: | 3834,12 |
| Cumulative IF for original publications in peer-reviewed journals: | 3043,14 |
| Cumulative IF for reviews in peer-reviewed journals: | 790,98 |
| Citations, Hirsch index: (view on Web of Science) | 26429 |